Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept quiet on NASH safety data disclosure concerns

This article was originally published in Scrip

Executive Summary

Intercept Pharmaceuticals is not commenting on reports that the company did not appropriately disclose safety information about its lead drug candidate obeticholic acid (OCA), but Intercept released a set of e-mail messages on 22 May that show the company knew about OCA's impacts on cholesterol in the investigator-sponsored FLINT trial as early as 6 January.

You may also be interested in...



Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk

After otherwise successful Phase II NASH trial showed Ocaliva can increase a patient's LDL cholesterol levels, Intercept hopes a study in NASH patients who use atorvastatin will show this effect is manageable.

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.

Stockwatch: Pandora’s Interim Analysis

The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel